What is the regulatory status of Melanotan I?

Melanotan I regulatory status: Approved (Scenesse implant for EPP) in the United States; WADA status not on prohibited list; research level phase iii in epp; off-label tanning use. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For healthspan and biological-age use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What is the evidence base for Melanotan I?

Melanotan I's evidence base sits at phase iii in epp; off-label tanning use. The references on this page summarise 1 primary publication supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The longevity / hallmarks of aging interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Is Melanotan I safe during pregnancy or breastfeeding?

Melanotan I, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

How should Melanotan I be stored and reconstituted?

Lyophilised Melanotan I stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

What does Melanotan I stack well with?

For longevity / hallmarks of aging protocols, Melanotan I pairs with compounds on complementary pathways: Epithalon, Thymalin, NAD+. These pairings are selected because they engage independent receptor systems from Melanotan I's primary mechanism (Selective melanocortin-1 receptor (MC1R) agonist), producing additive or synergistic effects rather than receptor competition.

Home/ Compounds/ Melanotan I

Melanotan I

Longevity

For users tracking biological age and healthspan-relevant biomarkers, Melanotan I sits within a multi-component longevity framework spanning hallmarks-of-aging from cellular (telomere, senescence, mitochondrial) through integrative (inflammaging, nutrient sensing). The non-cyclic α-MSH analogue with selective MC1R activity — FDA-approved as an implant for erythropoietic protoporphyria. Cycle-based dosing over 8-12 weeks with pre-post biomarker tracking is the longevity-research convention.

Longevity / Hallmarks of Aging Applications

NAD+ MetabolismHormesisSenescence ModulationmTOR ModulationStem Cell Function

Key Takeaways

Longevity lens: Melanotan I maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers.
Mechanism: Selective melanocortin-1 receptor (MC1R) agonist.
Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles.
Longevity protocol: cycle-based 0.5-1 mg 1x daily during loading; less frequent maintenance dosing; 8-12 week cycles favoured over continuous administration.
Longevity stack partners: Epithalon, Thymalin, NAD+.

Longevity / Hallmarks of Aging Mechanism

Selective melanocortin-1 receptor (MC1R) agonist. Increases eumelanin production in melanocytes. Provides photoprotection. Lacks the MC4R-mediated central effects (libido, appetite, sexual response) of Melanotan II. Hallmarks-of-aging mapping for Melanotan I: which of the nine hallmarks does this mechanism engage? The subsections below address Melanotan I's mapping to the hallmark framework, its effects on cellular reprogramming and gene expression, healthspan biomarker movement, and the cycle-based versus continuous dosing question that frames longevity-research protocol design.

Cellular reprogramming and gene expression

Where Melanotan I has measurable effects on transcriptional programmes, the direction of effect tends to be toward younger phenotypes rather than away from them. This signature — partial reversal of age-associated expression changes — is what distinguishes a true longevity-relevant compound from a symptomatic one. The signal strength varies, but the direction is what longevity researchers track.

Healthspan markers and biological age

For users measuring epigenetic age, telomere length, or composite biological-age markers (Horvath, PhenoAge, GrimAge) before and after Melanotan I cycles, the question is whether the intervention measurably moves these markers. Current evidence varies by compound but the framework for evaluation is shared: paired pre-post measurement with appropriate inter-test interval.

Cycle-based versus continuous dosing

Melanotan I's longevity protocol is compatible with either cycle-based or continuous dosing depending on the broader stack. The longevity-research convention favours pulsatile and periodic interventions over indefinite continuous administration, on the principle that hormetic stimulation outperforms sustained agonism for systems-biology-relevant endpoints.

Longevity / Hallmarks of Aging Applications

Autophagy Induction

Autophagy Induction maps to one of the hallmarks of aging and is one of the dimensions on which Melanotan I is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Cellular Reprogramming

For cellular reprogramming as a longevity-relevant endpoint, Melanotan I is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Nutrient Sensing

Melanotan I's contribution to nutrient sensing as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

Stem Cell Function

Stem Cell Function maps to one of the hallmarks of aging and is one of the dimensions on which Melanotan I is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	0.5-1 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1.5-1 mg	4–6 weeks initial cycle
Longevity focus	SubQ	0.5-1 mg	1x daily during loading; less frequent maintenance
Maintenance phase	SubQ	1.5-1 mg	Ongoing with periodic pauses

Dose timing for Melanotan I is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Melanotan I stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.

Melanotan I + Epithalon: Identified by Khavinson in St. Pairs naturally with Melanotan I's mechanism in longevity / hallmarks of aging protocols.
Melanotan I + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with Melanotan I's mechanism in longevity / hallmarks of aging protocols.
Melanotan I + NAD+: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Pairs naturally with Melanotan I's mechanism in longevity / hallmarks of aging protocols.
Melanotan I + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with Melanotan I's mechanism in longevity / hallmarks of aging protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Approved (Scenesse implant for EPP) Research: Phase III in EPP; off-label tanning use

Hyperpigmentation (intended). Nausea on initial doses. Watch for new/changing moles. Avoid in personal/family melanoma history.

Lens-specific safety considerations for longevity / hallmarks of aging use of Melanotan I: Hyperpigmentation (intended). Nausea on initial doses. Watch for new/changing moles. Avoid in personal/family melanoma history. Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Afamelanotide in erythropoietic protoporphyria

PMID 26177253

Melanotan I vs Related Peptides

Compound	Profile	Onset	Best For
Melanotan I	α-MSH analogue (long-acting)	~2-30 days (implant); ~30 min SubQ	Longevity
Epithalon	Pineal-derived tetrapeptide	Very short (minutes)	A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies
Thymalin	Thymic polypeptide extract	Variable	A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease
MOTS-c	Mitochondrially-encoded peptide	Hours; tissue-distributed	A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Does Melanotan I actually extend lifespan?

Direct lifespan extension in humans cannot be inferred from current data for any peptide compound. The relevant question is whether Melanotan I measurably moves healthspan-relevant biomarkers — epigenetic age, telomere length, inflammatory panels, metabolic flexibility — in the direction of younger phenotypes. Some compounds in this class have measurable effects on these markers; the lifespan extrapolation remains inferential.

When in life should I start Melanotan I?

Most longevity-relevant peptides have evidence bases centred on mid-life and later. Earlier use is theoretically reasonable for users with documented age-related markers (elevated inflammation, accelerated epigenetic age) or for compounds whose mechanism is preventative. Below age 35 the benefit for most longevity peptides is theoretical and warrants compound-specific consideration.

Does Melanotan I interact with rapamycin, metformin, or other longevity stacks?

Most peptide compounds are compatible with the standard longevity small-molecule stack (rapamycin, metformin, NAD precursors, senolytics in pulsed protocols). Interactions where present are typically additive rather than competitive. Verify case-specifically with a longevity-informed clinician.

Best stack pairing for longevity?

Layered protocols cover multiple hallmarks of aging simultaneously: pineal/telomere (epithalon), thymic/immune (thymalin), mitochondrial (MOTS-c, NAD+), ECM and gene expression (GHK-Cu), and metabolic flexibility (metformin-class or GLP-1-class as appropriate). Melanotan I contributes to its specific hallmark layer in this multi-component framework.

What should I look for in Melanotan I sourcing and quality?

Acceptable Melanotan I certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 1646 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

How long until I see results from Melanotan I?

Acute effects from Melanotan I appear within hours of dosing for receptor-level changes. healthspan and biological-age endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

Clinical Protocol

Start a Melanotan I Protocol

Alukard provides physician-supervised longevity protocols with GMP-certified Melanotan I and GMP-certified compounds with biological age testing and healthspan markers.

Get Protocol

Quick Facts

Molecular weight: 1646 Da
Sequence length: 13 aa
Half-life: ~2-30 days (implant); ~30 min SubQ
WADA: Not on prohibited list
FDA: Approved (Scenesse implant for EPP)
Research: Phase III in EPP; off-label tanning use

Stack Partners

Epithalon

Thymalin

NAD+

MOTS-c

GHK-Cu

Research Note

All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Melanotan I unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised longevity protocols

Start Your Longevity / Hallmarks of Aging Protocol for Melanotan I

Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised